Literature DB >> 28777372

p53 inhibits SP7/Osterix activity in the transcriptional program of osteoblast differentiation.

Natalia Artigas1, Beatriz Gámez1, Mónica Cubillos-Rojas1, Cristina Sánchez-de Diego1, José Antonio Valer1, Gabriel Pons1, José Luis Rosa1, Francesc Ventura1.   

Abstract

Osteoblast differentiation is achieved by activating a transcriptional network in which Dlx5, Runx2 and Osx/SP7 have fundamental roles. The tumour suppressor p53 exerts a repressive effect on bone development and remodelling through an unknown mechanism that inhibits the osteoblast differentiation programme. Here we report a physical and functional interaction between Osx and p53 gene products. Physical interaction was found between overexpressed proteins and involved a region adjacent to the OSX zinc fingers and the DNA-binding domain of p53. This interaction results in a p53-mediated repression of OSX transcriptional activity leading to a downregulation of the osteogenic programme. Moreover, we show that p53 is also able to repress key osteoblastic genes in Runx2-deficient osteoblasts. The ability of p53 to suppress osteogenesis is independent of its DNA recognition ability but requires a native conformation of p53, as a conformational missense mutant failed to inhibit OSX. Our data further demonstrates that p53 inhibits OSX binding to their responsive Sp1/GC-rich sites in the promoters of their osteogenic target genes, such as IBSP or COL1A1. Moreover, p53 interaction to OSX sequesters OSX from binding to DLX5. This competition blocks the ability of OSX to act as a cofactor of DLX5 to activate homeodomain-containing promoters. Altogether, our data support a model wherein p53 represses OSX-DNA binding and DLX5-OSX interaction, and thereby deregulates the osteogenic transcriptional network. This mechanism might have relevant roles in bone pathologies associated to osteosarcomas and ageing.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28777372      PMCID: PMC5686339          DOI: 10.1038/cdd.2017.113

Source DB:  PubMed          Journal:  Cell Death Differ        ISSN: 1350-9047            Impact factor:   15.828


  58 in total

Review 1.  Building strong bones: molecular regulation of the osteoblast lineage.

Authors:  Fanxin Long
Journal:  Nat Rev Mol Cell Biol       Date:  2011-12-22       Impact factor: 94.444

2.  p53 loss increases the osteogenic differentiation of bone marrow stromal cells.

Authors:  Yunlong He; Luis F de Castro; Min Hwa Shin; Wendy Dubois; Howard H Yang; Shunlin Jiang; Pravin J Mishra; Ling Ren; Hongfeng Gou; Ashish Lal; Chand Khanna; Glenn Merlino; Maxwell Lee; Pamela G Robey; Jing Huang
Journal:  Stem Cells       Date:  2015-04       Impact factor: 6.277

3.  The p38 MAPK pathway is essential for skeletogenesis and bone homeostasis in mice.

Authors:  Matthew B Greenblatt; Jae-Hyuck Shim; Weiguo Zou; Despina Sitara; Michelle Schweitzer; Dorothy Hu; Sutada Lotinun; Yasuyo Sano; Roland Baron; Jin Mo Park; Simon Arthur; Min Xie; Michael D Schneider; Bo Zhai; Steven Gygi; Roger Davis; Laurie H Glimcher
Journal:  J Clin Invest       Date:  2010-06-14       Impact factor: 14.808

4.  Sp7/Osterix Is Restricted to Bone-Forming Vertebrates where It Acts as a Dlx Co-factor in Osteoblast Specification.

Authors:  Hironori Hojo; Shinsuke Ohba; Xinjun He; Lick Pui Lai; Andrew P McMahon
Journal:  Dev Cell       Date:  2016-04-28       Impact factor: 12.270

5.  Crystal structure of a p53 tumor suppressor-DNA complex: understanding tumorigenic mutations.

Authors:  Y Cho; S Gorina; P D Jeffrey; N P Pavletich
Journal:  Science       Date:  1994-07-15       Impact factor: 47.728

6.  Dlx5 and mef2 regulate a novel runx2 enhancer for osteoblast-specific expression.

Authors:  Tetsuya Kawane; Hisato Komori; Wenguang Liu; Takeshi Moriishi; Toshihiro Miyazaki; Masako Mori; Yuki Matsuo; Yoshio Takada; Shinichi Izumi; Qing Jiang; Riko Nishimura; Yosuke Kawai; Toshihisa Komori
Journal:  J Bone Miner Res       Date:  2014-09       Impact factor: 6.741

7.  The impact of osteoblastic differentiation on osteosarcomagenesis in the mouse.

Authors:  T Quist; H Jin; J-F Zhu; K Smith-Fry; M R Capecchi; K B Jones
Journal:  Oncogene       Date:  2014-10-27       Impact factor: 9.867

8.  Regulation of the osterix (Osx, Sp7) promoter by osterix and its inhibition by parathyroid hormone.

Authors:  Richard Barbuto; Jane Mitchell
Journal:  J Mol Endocrinol       Date:  2013-06-18       Impact factor: 5.098

9.  p53 plays a role in mesenchymal differentiation programs, in a cell fate dependent manner.

Authors:  Alina Molchadsky; Igor Shats; Naomi Goldfinger; Meirav Pevsner-Fischer; Melissa Olson; Ariel Rinon; Eldad Tzahor; Guillermina Lozano; Dov Zipori; Rachel Sarig; Varda Rotter
Journal:  PLoS One       Date:  2008-11-12       Impact factor: 3.240

10.  Osteoblast differentiation and skeletal development are regulated by Mdm2-p53 signaling.

Authors:  Christopher J Lengner; Heather A Steinman; James Gagnon; Thomas W Smith; Janet E Henderson; Barbara E Kream; Gary S Stein; Jane B Lian; Stephen N Jones
Journal:  J Cell Biol       Date:  2006-03-13       Impact factor: 10.539

View more
  21 in total

1.  Role of p53 deficiency in socket healing after tooth extractions.

Authors:  Xiaohan Yang; Zhixuan Zhou; Zhiyuan Mao; Ming Shen; Ning Chen; Dengshun Miao
Journal:  J Mol Histol       Date:  2020-01-31       Impact factor: 2.611

2.  CircPOMT1 and circMCM3AP inhibit osteogenic differentiation of human adipose-derived stem cells by targeting miR-6881-3p.

Authors:  Xin-Qi Huang; Xiao Cen; Wen-Tian Sun; Kai Xia; Li-Yuan Yu; Jun Liu; Zhi-He Zhao
Journal:  Am J Transl Res       Date:  2019-08-15       Impact factor: 4.060

3.  A novel long noncoding RNA PGC1β-OT1 regulates adipocyte and osteoblast differentiation through antagonizing miR-148a-3p.

Authors:  Hairui Yuan; Xiaowei Xu; Xue Feng; Endong Zhu; Jie Zhou; Guannan Wang; Lijie Tian; Baoli Wang
Journal:  Cell Death Differ       Date:  2019-02-06       Impact factor: 15.828

4.  Peonidin-3-O-glucoside and cyanidin increase osteoblast differentiation and reduce RANKL-induced bone resorption in transgenic medaka.

Authors:  Zhitao Ren; Nishikant A Raut; Temitope O Lawal; Shital R Patel; Simon M Lee; Gail B Mahady
Journal:  Phytother Res       Date:  2021-10-26       Impact factor: 5.878

5.  Wnt/ß-catenin-mediated p53 suppression is indispensable for osteogenesis of mesenchymal progenitor cells.

Authors:  Xin Zhou; Allyson Beilter; Zhaohui Xu; Ruli Gao; Shunbin Xiong; Adriana Paulucci-Holthauzen; Guillermina Lozano; Benoit de Crombrugghe; Richard Gorlick
Journal:  Cell Death Dis       Date:  2021-05-21       Impact factor: 8.469

6.  MiR-16-5p regulates postmenopausal osteoporosis by directly targeting VEGFA.

Authors:  Tao Yu; Xiaomeng You; Haichao Zhou; Wenbao He; Zihua Li; Bing Li; Jiang Xia; Hui Zhu; Youguang Zhao; Guangrong Yu; Yuan Xiong; Yunfeng Yang
Journal:  Aging (Albany NY)       Date:  2020-05-19       Impact factor: 5.682

7.  Tolerance to sustained activation of the cAMP/Creb pathway activity in osteoblastic cells is enabled by loss of p53.

Authors:  Mannu K Walia; Scott Taylor; Patricia W M Ho; T John Martin; Carl R Walkley
Journal:  Cell Death Dis       Date:  2018-08-28       Impact factor: 8.469

Review 8.  From the Performance to the Essence: The Biological Mechanisms of How Tantalum Contributes to Osteogenesis.

Authors:  Hu Qian; Ting Lei; Zhimin Ye; Yihe Hu; Pengfei Lei
Journal:  Biomed Res Int       Date:  2020-07-27       Impact factor: 3.411

9.  ZNF185 is a p53 target gene following DNA damage.

Authors:  Artem Smirnov; Angela Cappello; Anna Maria Lena; Lucia Anemona; Alessandro Mauriello; Nicola Di Daniele; Margherita Annicchiarico-Petruzzelli; Gerry Melino; Eleonora Candi
Journal:  Aging (Albany NY)       Date:  2018-11-16       Impact factor: 5.682

10.  Myoblasts rely on TAp63 to control basal mitochondria respiration.

Authors:  Veronica Ciuffoli; Anna Maria Lena; Alessandra Gambacurta; Gerry Melino; Eleonora Candi
Journal:  Aging (Albany NY)       Date:  2018-11-28       Impact factor: 5.682

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.